ClinicalTrials.gg
CompletedNCT04710407Updated Mar 16, 2021

Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) Concentrations Following the Oral Administration of Five Doses of SPR994 in Healthy, Nonsmoking Volunteers

A Phase 1 interventional study of TBPM-PI-HBr in Healthy Volunteers, sponsored by Spero Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-16.

Sponsored by Spero Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2021, 5 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

To evaluate the intrapulmonary pharmacokinetics (PK), including ELF and AM concentrations, of SPR859 (tebipenem) compared to plasma concentrations of SPR859 (tebipenem) (the active moiety in plasma of the prodrug SPR994) in nonsmoking healthy adult volunteers.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • pharmacokinetics
  • TBPM-PI-HBr
  • tebipenem
  • alveolar macrophages (AM)
  • epithelial lining fluid (ELF)
  • intrapulmonary
03

In context

Lead sponsor

Spero Therapeutics is the lead sponsor of 22 studies on the registry; none are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 3 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult males or female subjects, between 18 and 55 years of age (both inclusive) at the time of screening
  • ≥ 18.5 and ≤ 32 (kg/m2) and weight between 55.0 and 100.0 kg (both inclusive)
  • Willing and able to provide written ; Willing and able to comply with all study assessments and adhere to the protocol schedule
  • Medically healthy without abnormalities as assessed by the Investigator based on screening medical history, physical examination, vital signs, 12-lead , hematology, biochemistry and urinalysis
  • Have suitable venous access for blood sampling

Exclusion criteria

Exclusion Criteria:

  • History of seizure disorders
  • Positive urine drug, alcohol or cotinine testing at screening or check-in (Day -1)
  • Positive testing for (HIV), surface antigen (HBsAg) or antibodies (HCV);
  • Positive testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at screening;
  • Presence of the following symptoms at screening or within 14 days prior to screening or Check-in (Day -1)

    1. Fever, chills or sweats (temperature of 38 °C / 100.4 °F or higher)
    2. Difficulty breathing
    3. Cough
    4. Sore throat
    5. New or recent loss of taste or smell
    6. Nausea, vomiting or diarrhea;
  • Close contact with anyone who tested positive for SARS-CoV-2 infection within 14 days prior to screening or Check-in (Day -1);
  • (ECG) with interval duration equal or greater than 450 msec for males and 470 msec for females
  • Subjects who have any of the following abnormalities on laboratory values at screening or prior confinement including:

    1. White blood cell count \< 3,000/mm3, \< 11g/dL;
    2. \<1,200/mm3, count \<120,000/mm3;
    3. (ALT) and aspartate aminotransferase (AST) greater than 1.5 x the (ULN) for the reference laboratory;
  • History of substance abuse or alcohol abuse
  • Use of tobacco/nicotine- or marijuana-containing products (including vaping products) within 12 months prior to screening;
  • Known history of reaction or anaphylaxis to any medication
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    TBPM-PI-HBr

    Healthy subjects meeting eligibility criteria will receive a total of five doses of TBPM-PI-HBr 600 mg orally every 8 hours.

    Drug: TBPM-PI-HBr

Interventions

  • TBPM-PI-HBr (2 x 300mg tablets) a total of five doses

    Also known as: TBPM-PI-HBr oral capsule, SPR994

06

What researchers measure

Primary outcomes

  1. Plasma PK and lung penetration of SPR859 following multiple doses

    Plasma PK parameters will include the area under the curve (AUC) from time zero to the last quantifiable sample (AUC0-t), AUC from time zero to end of dosing interval (AUC0-8). The AUC0-8 values for ELF and AM will be determined. The ratios of the AUC0-8 of ELF to the AUC0-8 of plasma and the AUC0-8 of AM to the AUC0-8 of plasma will be calculated.

    Time frame: Day 1 to Day 3

  2. Plasma PK and lung penetration of SPR859 following multiple doses

    Plasma PK parameters will include the maximum concentration (Cmax), minimum concentration (Cmin), time to Cmax (tmax), and the terminal-phase half-life (t1/2).

    Time frame: Day 1 to Day 3

Secondary outcomes

  1. Safety and tolerability, including adverse events (AEs)

    Frequency of adverse events by severity, seriouness, system organ class, preferred term and treatment group

    Time frame: Day 1 to Day 10

  2. Safety and tolerability, including clinically significant changes from baseline in clinical laboratory values

    Change from baseline in selected laboratory assays including WBC, hemoglobin, platelet count, liver function tests (AST, ALT, AP), blood urea nitrogen (BUN), serum creatinine (Cr), and estimated Cr clearance (based on Cockcroft-Gault formula), by treatment group

    Time frame: Day 1 to Day 10

  3. Safety and tolerability, including physical examination

    Change from baseline in vital signs

    Time frame: Day 1 to Day 10

  4. Safety and tolerability, including ECG

    Cardiac (12-Lead ECG) will be summarized at each scheduled time point using descriptive statistics

    Time frame: Day 1 to Day 10

07

Study locations

1 site
  • Pulmonary Associates
    Phoenix, Arizona 85032, United States
08

References and documents

Publications

  • Rodvold KA, Gotfried MH, Gupta V, Ek A, Srivastava P, Talley A, Bruss J. Plasma and Intrapulmonary Concentrations of Tebipenem following Oral Administration of Tebipenem Pivoxil Hydrobromide to Healthy Adult Subjects. Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0059022. doi: 10.1128/aac.00590-22. Epub 2022 Jun 28. PubMed 35762796 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Mar 2021, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2021
First posted
Jan 14, 2021
StartActual
Dec 7, 2020
Primary completionActual
Mar 10, 2021
CompletionActual
Mar 10, 2021
Last update
Mar 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04710407
Lead sponsor
Spero Therapeutics
Collaborators
Clinartis
Responsible party
Sponsor
First posted
Jan 14, 2021
Start date
Dec 7, 2020
Primary completion
Mar 10, 2021
Completion
Mar 10, 2021
Last update
Mar 16, 2021

Study contacts

David Baratz, MD
principal investigator · Pulmonary Associates

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tebipenem

Start the discussion